SINTOPRAM OS GTT 15ML ML 40mg
Active CITALOPRAM HYDROCHLORIDE ANTIDEPRESSANTS
therapeutic
Group Product Type Ethical Regime SSN CONCEDIB.ESENTE
Class A Recipe Type RR - Repeat
Form Farm. DROPS OS / OS container LIQUID DROPPER VIAL
Commerc Data valid for 24 months. 21/07/2006 Price
ATC N06AB04
The product contains no gluten gluten
Manufacturer BIOMEDICAL FOSCAMA IND.CFSpA
Pharmacotherapeutic
antidepressants. INDICATIONS
endogenous depressive syndromes and relapse prevention and rico
rrenze. Anxiety disorder with panic attacks, with or without agoraphobia.
CONTRAINDICATIONS / EFF.SECONDAR
hypersensitivity 'to the active substance or to any of eccipien
you. Eta 'than 18 years. Citalopram should not be somministrat
or patients taking MAO inhibitors, but not before
14 days after their discontinuation. Generally contraindicated in gra
nancy and lactation.
DOSAGE
depressive syndromes endogenous. Adults:
is administered in a single daily dose. The initial dose 'of 16 mg (8 drops) per day,
evening. On the basis of individual clinical response, this can 're
they increased to 32 mg / day (16 drops). Only if necessary, the dose
will be able to 'be further increased to 48 mg / day (24 drops)
maximum dose. The antidepressant effect usually occurs within 2-4 if
ttimane start of therapy, and 'should the patient be followed by
doctor until remission of depression. Since 'the
the treatment with antidepressant and' symptomatic, should be continuatio
or for an appropriate period of time, usually 4-6 months in
ie manic-depressive illness. In patients with unipolar depression and can
THE APPLICANTS 'need to continue maintenance therapy for LUNs go
term to prevent a recurrence of depression. Disorders in
nsia with panic attacks, with or without agoraphobia. The initial dose and '
8 mg (4 drops) per day. After one week the dose may 'be au
lied to 16 mg (8 drops) per day. The optimal daily dose and
'standard of 16 mg (8 drops) -24 mg (12 drops). In case of insufficient response the dose may
'be increased to a maximum of 48 m
g (24 drops) per day. Panic disorders with the trattament
o 'a long term. The maintenance of clinical response and '
been demonstrated during prolonged treatment (1 year). In the case of unsustainable
nnia or severe restlessness is recommended additional treatment with sedatives
in the acute phase. When you decide to stop treatment
ation doses should be reduced gradually to minimize the
entities' withdrawal symptoms. Elderly: Patients over 65 years of age
ni 'should be given half' of the recommended dose ac
Ausa a slowed metabolism. Subjects aged 'under 18 an ni
: Sintopram should not be used for the treatment of subjects
the under 18 years of age'. Hepatic impairment: In patients with hepatic and
's not recommend a daily dose of 20-30 mg
uperiore. Renal failure in these patients and 'con
be advisable to follow minimum recommended dosage. We must avoid a '
abrupt termination of treatment. When stopping treatment with sintopram
to the dose should be gradually reduced over a period of at least two weeks
or to reduce the risk of a reaction
nsione susp. If you experience following the reduction of the d ose
or at the time of treatment, symptoms will not tolerate
disabled, you can 'take into account the restoration of pre dose
written above. Then your doctor may 'continue to rid
Urrea dose, but in a more' gradual.
WARNINGS
Coadministration of SSRIs and MAO inhibitors can 'cause
and serious adverse reactions, some fatal, and the appearance of hypertension crisis
sive. Therefore, citalopram should not be administered to patients in
treatment with MAO inhibitors, but not before at least 14 days after their discontinuation
. A treatment with MAO inhibitors can '
be initiated 7 days after discontinuation of citalopram.
if the patient enters a manic phase, treatment should be discontinued and
must establish an appropriate treatment with neuroleptics
us. The risk of suicide in depressed patients persists until
or you do not get a significant remission, since 'blocking inhibition
thorium can' be less than before they establish themselves in effective ant
idepressiva. It 'important to closely monitor the patient during the initial period
. Some patients with anxiety disorders with
crisis of the panic may report an accentuation of symptoms of anxiety INI
uncle of treatment with antidepressants. This paradoxical increase in symptoms of anxiety and
me 'more' marked during the first days of therapy and disappears
and with continued treatment (usually within two weeks). Q
hen abruptly treatment with inhibitors of wealth
aptazione serotonin may appear insomnia, dizziness, sudo
ration, palpitations, nausea, anxiety, irritability ', paresthesia, and Cephas
lea, so when you decide to stop treatment
doses should be reduced gradually to minimize the institutions
ta 'of such symptoms. Be careful not to interpret these symptoms
attributable to a worsening of psychiatric illness treated
. Side effects may be more 'frequent during the use of contemporary
serotonin reuptake inhibitors (SSRIs
) nefazodone, trazodone, triptans and preparations of Hypericum p
erforatum. The drugs belonging to the initial class of antidepressants
BITOR serotonin reuptake should be administered with care when
canvas in patients who received concomitant anticoagulants, drugs that affect platelet aggregation
(NSAIDs, aspirin co
, ticlopidine, etc..) or other drugs that may I
increase the risk of bleeding. In addition, these drugs should be administered with care when
canvas in patients with a history of bleeding disorders. Pazi
institutions with hepatic impairment should begin treatment with a
low dose and be carefully monitored. In patients with
breathes 'sharply reduced kidney and' follow the recommended dosages or
recommended minimum. The drug should be discontinued if the
observed an increase in the frequency of seizures.
in patients with the diabetes, a therapy of SSRIs may 'alter the control g
licemico, this could be a consequence of improved
depression. It 'may need to adjust the dose of insulin
and / or oral antidiabetics. It contains para-hydroxybenzoates
which may cause allergic reactions, usually
delayed type. The product contains 9 vol% ethanol. A dose
can 'hold up 0.09 g of ethanol (maximum dose). Bad for those
patients suffering from liver diseases, alcoholism, epilepsy,
lesions or brain disease or pregnant women and children. Can 'm
odificare or increase the effect of other medicines. Depression and '
associated with increased risk of suicidal thoughts, self harm and suicide
(suicide / related events). This risk persists until he ac
significant remission occurs. Since 'can not
ficarsi real improvement during the first weeks of treatment or q
uelle immediately, patients should be closely monitored until such improvement
. E 'clinical experience in
that the risk of suicide can' increase in the early stages of
improvement. Other psychiatric for which Sintopram
and 'prescribed may be associated with an increased risk of suicidal rtamento
components. Moreover, these conditions may be Associat
and major depressive disorder.
patients with a history of suicidal behavior or thoughts, or those exhibiting a significant degree cannot
of suicidal ideation prior to treatment,
are at increased risk of suicidal ideation or suicide attempts,
and must be carefully controlled during treatment. I paz
othing (or whoever takes care of them) should be warned of
need 'to monitor and report immediately to their physician any med
ico clinical worsening, the onset of the
behavior or suicidal thoughts or behavior change. The use of
Sintopram and 'was associated with the development of akathisia, dear
tterizzata a feeling of inner restlessness and psychomotor agitation
such as inability' to sit or stand still, it generates
lment associated with subjective discomfort. This' and 'more' likely ac
fall within the first weeks of treatment. In patients who develop these
no symptoms, increasing the dose may 'be harmful. The heating
hio of onset of withdrawal symptoms can 'f
dependent on several actors, including the duration of therapy, the dosage and the rate r
EDUCING dose. Dizziness, trouble sens
orio, sleep disturbances (including insomnia and intense dreams), agitazion
/ or anxiety, nausea and / or vomiting, tremor, confusion, sweating, a mullet
, diarrhea, palpitations, instability 'emotional , irritability ', and
, trouble with vision impairments. Generally, the intensity 'of these symptoms and'
mild to moderate, however, some patients may 'be serious. Typically c
defects appear within the first few days of discontinuing treatment, but you know
not been very rare reports of such symptoms in patients who had no
inadvertently missed a dose. Generally these symptoms are
uto-limiting, and usually resolve within two weeks, although
n some individuals may take more than 'long (2-3 months or more'). Sint
opram should not be used to treat the subject of
under 18 years of age '. Suicidal behavior (suicide attempts to suicidal ideation
oe) and hostility '(predominantly aggression,' comp
ortamento opposition and anger) were observed with greater frequency
in clinical trials in children and adolescents treated with antidepressants
results than those treated with placebo. Where to
, based on clinical need, the decision should be taken and
ffettuare treatment, the patient should be monitored attentam
institution with regard to the appearance of suicidal symptoms. What's more, '
no data are available on long-term safety for children
ie for adolescents concerning growth, maturation and cognitive development and behavioral
.
INTERACTIONS
The biotransformation of citalopram in demetilcitalopram and 'dag
them mediated cytochrome P450 isoenzymes, CYP2C19 (60%), CYP3A
4 (30%) and CYP2D6 (approximately 10%). Inhibition of the
isoenzymes CYP2C9, CYP2E1 and CYP3A4 by citalopram and demetilcitalopram
and 'negligible and the two compounds are only weak inhibitors of Isoe
nzima CYP1A2, CYP2C19 and CYP2D6 than other SSRIs, with which 'was to
demonstrated significant inhibition. Therefore, and 'unlikely ch
and citalopram inhibit P450-mediated metabolism of drugs in therapeutic doses
. Concurrent administration of MAO inhibitors, including
including reversible MAOIs (RIMA) such as moclobemide, may
or 'cause serious adverse reactions, some fatal, which Ive
hypertensive crisis or serotonin syndrome. There were no reported interaction
ni linked to concomitant use of alcohol. Cimetidine
deter mine a modest increase in the average levels of citalopram state stat
JPEG low. It is therefore advised to exercise caution when
administered therapeutic dosages most 'high citalopram in ass
ociazione at high doses of cimetidine (
potent inhibitor of CYP2D6, CYP3A4). There have been reports of potentiation of the effects q
hen SSRIs are administered with lithium or tryptophan
, therefore, and 'Caution should be exercised when these drugs are used simultaneously
. The drugs belonging to the class of
he serotonin reuptake inhibitor antidepressants
ono poss increase the risk of bleeding when administered concurrently with the
n anticoagulants or drugs that affect platelet aggr
egazione (NSAIDs, aspirin, ticlopidine, etc.).
. A study of the pharmacokinetics and pharmacodynamic interaction between c
italopram and metoprolol (a CYP2D6 substrate) showed a doubly rad
concentrations of metoprolol, but no increase Mr
ning of the effects of metoprolol on blood pressure and heart rate in
lla healthy volunteers. The concomitant administration of other serotonergic
ante, such as tramadol and sumatra
iptan, can 'enhance 5-HT associated effects. Were effettuat
the pharmacokinetic interaction studies with levomepromazine (
ibitore in a prototype of CYP2D6 and phenothiazines), and with the
mipramina (a partial inhibitor of CYP2D6, a prototype of tricyclic antidep
interests). There were no interactions with nature to
macocinetica clinical importance.
SIDE EFFECTS The side reactions are observed in general was mild 'and
transitory. They occur mainly in the first or second week of therapy
wave, and disappeared with the improvement of
depression. Frequent side effects (> 1% - <10%) sono
: Metabolism and nutrition disorders: decreased appetite, dist
urbi Psychiatric abnormality and decreased libido '
orgasm (women), nervous system disorders: agitation, insomnia, a sonnolenz
, dizziness, respiratory disorders: yawning; g
astrointestinali disorders: nausea, dry mouth, diarrhea, constipation; affe
tions of the skin and subcutaneous tissue disorders: sweating increased
; disorders of 'reproductive system: abnormal ejaculates
tion, impotence, deterioration of physical conditions: affaticame
nt. Very rare side effects (endocrine <1/10.000) sono: disturbi dell'a
ppar: inappropriate secretion of ADH (especially in women older
), metabolic disorders and nutrition: hyponatremia;
disturb the nervous apparatus: seizures, extrapyramidal disorders, skin and fond
oni subcutaneous tissue bruising, purple comprom
ission of the General Conditions: hypersensitivity reactions, 'ome
serotonin syndrome, withdrawal symptoms (dizziness, nausea and paraesthesia
ie). Rarely, after administration of antidepressants ini
BITOR serotonin reuptake can occur randomly selected manuf
bleeding as bruising, bleeding gynecological manifestations
stations bleeding in the gastrointestinal tract, the mucus
or even if other districts' s body . When interrupts b
rusca treat withdrawal symptoms may appear.
These symptoms are usually mild and complete resolution and uptake
or, for example: insomnia, dizziness, sweating, palpitations, nausea,
anxiety, irritability ', paresthesias, and headache. When you decide to break the inter
treatment doses should be reduced gradually to minimize
'entity' of such symptoms.
Other side effects that have been observed with SSRIs are: cardiovascular
are: postural hypotension, disorders of the eye: abnormality 'of you is
, gastrointestinal: vomiting, hepato-biliary disorders:
tion alters function tests' liver , musculo-skeletal
us: arthralgia, myalgia, and psychiatric disorders: hallucinations, mania, c
onfusione, anxiety, depersonalization, panic attacks, nervousness,
urinary disorders: urinary retention, ego disturbance
ppar Reproductive: galactorrhea, diseases of the skin and subcutaneous tissue
itching. It 'was reported hyponatremia,
probably due to inappropriate secretion of antidiuretic hormone, as r
eaction rare adverse to the use of SSRIs. It seems that older women cost
ituiscano a group particularly at risk. E 'was rarely winged Signal
a serotonin syndrome in patients treated with SSRIs.
the appearance of a number of symptoms, including agitation, confusion, t
hesitation, myoclonus and hyperthermia, may be the precursors of the s
indrome.
PREGNANCY AND LACTATION
The harmlessness 'of citalopram in pregnancy is not' been established. Sebbe
it's animal studies have not shown signs of potential teratogenicity
', it' effects on reproduction or on co
ndizioni perinatal, since 'the citalopram and its metabolites
pours through the placenta and a small amount' is
found in breast milk is not recommended for use during pregnancy and to
llattamento.
0 comments:
Post a Comment